China boosts combat capability in Tibetan Plateau

Agencies
August 14, 2018

Beijing, Aug 14: The Chinese military has set up oxygen stations and introduced high-pressure oxygen therapy and specially designed portable barracks to its troops stationed in the Qinghai-Tibet Plateau to boost combat capability in the high-altitude ranges where oxygen levels are low, official media here reported today.

Chinese official media had been periodically highlighting the training preparations and the combat readiness of the PLA troops in Tibet in the recent months.

According to the official People's Liberation Army (PLA) website 81.cn, all frontline training troops and border outposts have been equipped with oxygen generators and oxygen cylinders.

Also, the Army Medical University's Xinqiao Hospital in Xigaze, which is close to the Line of Actual Control (LAC) with India, is developing a high-pressure oxygen therapy that could effectively solve altitude stress for troops stationed on the plateau, the PLA Daily said.

It said that oxygen therapy, used to cure brain damage and carbon monoxide poisoning, can be calibrated for high altitude.

The improved therapy has proved effective against altitude stress. Oxygen stations have been built along border roads for soldiers to recover stamina, the state-run Global Times reported today.

"Altitude stress makes troops have breathing difficulties, results in headaches and insomnia," the daily quoted a former military officer who served in Tibet as saying.

Thin air damages combat capability, lowers troops' strength and durability, Song Zhongping, a military expert and TV commentator, told the newspaper.

Applying oxygen therapy helped soldiers to recover in the harsh conditions and enhanced their combat capabilities, he said.

Last month, the PLA Daily reported that the special forces of the Chinese military had conducted drills in Tibet, including ground training for helicopter pilots, to test their skills.

In June, Chinese military units stationed in Tibet carried out a drill, the first post-Dokalam, to test their logistics, armament support capabilities as well as military-civil integration in Tibet.

Earlier, official media had reported about China setting up an unmanned automatic weather observation station in Tibet, close to its border with Arunachal Pradesh, to provide meteorological support for its fighter jets and missile launches.

According to a latest 81.cn report, the PLA is also improving troops' quality of life.

Beginning last year, it has been replacing the old pre-fabricated houses at Tibetan military bases with portable barracks, specifically designed for plateau areas.

The barracks' design and material make them sturdy, moisture-proof and cold-resistant, even keep the room temperature at 15 degrees Celsius even in the worst of snow storms, the report said.

Equipped with cutting-edge camouflage nets, the barracks are difficult to detect and suitable for field operations, the website reported.

Many soldiers and officers suffer frostbite in Tibet, the former military officer said, noting the new facilities provide strong logistical support and ensured the troops' combat capability.

New barracks and other improvements can let troops have enough rest and guarantee their quality of life so that they can work together with better morale, according to Song.

"Logistical support is essential to plateau combat," he said. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
June 25,2020

Islamabad, Jun 25: The coronavirus cases in Pakistan crossed the 192,000-mark after 4,044 new Covid-19 infections were detected in the last 24 hours, the health ministry said on Thursday.

According to the Ministry of National Health Services, 148 more people died due to the deadly virus in the country, taking the death toll to 3,903.

With the detection of 4,044 new cases in the last 24 hours, the coronavirus tally in the country now stands at 192,970, it said.

Sindh reported a maximum number of 74,070 infections, followed by 71,191 in Punjab, 23,887 in Khyber-Pakhtunkhwa, 11,710 in Islamabad, 9,817 in Balochistan, 1,365 in Gilgit-Baltistan and 930 in Pakistan-occupied Kashmir.

A total of 81,307 patients have recovered so far from the disease.

Health authorities have so far conducted 1,171,976 coronavirus tests, including 21,835 in the last 24 hours.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 2,2020

Washington, Apr 2: The total US death toll from the coronavirus pandemic topped 4,000 early Wednesday, more than double the number from three days earlier, according to a tally by Johns Hopkins University.

The number of deaths was 4,076 -- more than twice the 2,010 recorded late Saturday.

More than 40 percent of recorded deaths nationally were in New York state, the Johns Hopkins data showed.

On Tuesday the United States exceeded the number of deaths in China, where the pandemic emerged in December before spreading worldwide.

The number of confirmed US cases has reached 189,510, the most in the world, though Italy and Spain have recorded more fatalities.

After initially downplaying the threat from new coronavirus in the early stages of the US outbreak, President Donald Trump warned of "a very, very painful two weeks" to come for the country on Tuesday.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.